Diagnostic value for peanut per study and diagnostic test

Studies per section graded on 1) best quality assessment, 2) year of publication review (18)
Cut-off	Study	Country	Criteria suspicion PA^	TP	FP	TN	FN	Se	Sp	LR+	LR-
Skin prick test
3mm	Johannsen 2011	Australia	Pos SPT/sIgE without previous ingestion	24	14	11	0	100	44	1.79	0
	Kagan 2003	Canada	SPT ≥ 3 mm without previous ingestion	23	24	0	0	100	0	1	-
	Nolan 2007	Australia	Pos history or pos SPT/sIgE without previous ingestion	17	11	16	1	94	95	2.32	0.09
	Dunn, Galvin 2011	Ireland and UK	Pos history or pos sIgE without previous ingestion	58	19	38	9	85	67	2.60	0.20
	Klemans 2013	Nether-lands	Pos history, regardless of sensitization	31	16	17	16	66	52	1.38	0.65
	Wainstein 2007	Australia	Pos SPT, regardless of history	52	33	0	0	100	0	1	-
	Roberts 2005	UK	1) ‘Suspected PA’ 2) Pos SPT and pos history or no previous ingestion	50	13	55	17	75	81	3.91	0.31
	Ludman 2013	Switzer-land	Pos IgE/SPT without previous ingestion	9	8	3	1	90	27	1.24	0.37
8mm	Peters 2013*	Australia	SPT ≥ 1 mm compared to neg control	?	?	?	?	54	98	22.2	0.47
sIgE to peanut extract
0.23 kU/l	Dang # 2012	Australia	SPT ≥ 1 mm compared to neg control	95	30	28	5	95	49	1.80	0.10
0.35 kU/l	Johannsen 2011	Australia	Pos SPT/sIgE without previous ingestion	23	18	6	1	96	25	1.28	0.17
	Ebisawa 2012	Japan	Pos history or pos sensitization	26	24	7	0	100	23	1.29	0
	DunnGalvin 2011	Ireland and UK	Pos history or pos sIgE without previous ingestion	50	31	26	17	75	46	1.37	0.56
	Glaumann 2012	Sweden	Pos history and pos SPT/sIgE	25	9	4	0	100	31	1.45	0
	Eller 2013	Denmark	Pos history	± 166	± 30	± 0	± 9	95	0	0.95	-
	Lieberman 2013	US	Pos history and pos SPT/sIgE (and pos FC in some patients)	99	51	10	7	93	17	1.12	0.41
	Perry** 2004	US	Pos history (tolerance was suspected)	44	28	29	9	83	51	1.69	0.33
	Perry** 2004	US	Pos SPT/sIgE or unclear history (tolerance was suspected)	16	26	15	2	89	37	1.40	0.30
	Wainstein 2007	Australia	Pos SPT, regardless of history	51	22	11	1	98	33	1.47	0.06
	Lopes de O. 2013	Germany	?	34	27	0	0	100	0	1	-
	Bernard 2003	France	Pos history < 12 months	66	12	8	5	93	40	1.55	0.18
	Roberts 2005	UK	1) ‘Suspected PA’ 2) Pos SPT and pos history or no previous ingestion	59	23	39	15	80	63	2.15	0.32
	Nicolaou 2011	UK	1) Pos SPT/sIgE regardless of ingestion 2) Pos history and (SPT ≥ 8 mm and/or sIgE ≥ 15 kU/l)	28	38	14	1	97	27	1.32	0.13
24.1 kU/l	V Nieuwaal 2010	Nether-lands	Pos history or pos sIgE/SPT without previous ingestion	27	1	46	29	48	98	23.0	0.53
34 kU/l	Peters 2013*	Australia	SPT ≥ 1 mm compared to neg control	unk	unk	unk	unk	14	99	11.2	0.87
sIgE to Ara h 1 single-plexed assay
0.35 kU/l	Ebisawa 2012	Japan	Pos history or pos sensitization	10	7	24	16	38	77	1.70	0.79
	Glaumann 2012	Sweden	Pos history and pos SPT/sIgE	23	2	11	2	92	85	5.97	0.09
	Eller 2013	Denmark	Pos history	± 101	± 12	± 18	± 74	58	60	1.44	0.71
	Lieberman 2013	US	Pos history and pos SPT/sIgE (and pos FC in some patients)	59	8	53	47	56	87	4.31	0.51
	Bernard 2003	France	Pos history < 12 months	38	1	19	33	54	95	10.7	0.49
	Suratannon 2013	Thailand	Sensitization regardless of history/ingestion	5	1	20	14	26	95	5.48	0.77
sIgE to Ara h 1 multiplexed microarray
0.30 ISU/l	Lopes de O. 2013	Germany	?	29	16	11	3	91	41	1.84	0.23
sIgE to Ara h 2 single-plexed assay
0.35 kU/l	Ebisawa 2012	Japan	Pos history or pos sensitization	23	5	26	3	88	84	5.50	0.14
	Klemans 2013	Nether-lands	Pos history or pos sIgE/SPT without previous ingestion	43	15	38	4	91	72	3.23	0.12
	Glaumann 2012	Sweden	Pos history and pos SPT/sIgE	24	2	11	1	96	85	6.23	0.05
	Eller 2013	Denmark	Pos history	± 155	± 12	± 18	± 20	89	60	2.22	0.19
	Klemans 2013	Nether-lands	Pos history, regardless of sensitization	32	5	28	21	60	85	4.00	0.47
	Lieberman 2013	US	Pos history and pos SPT/sIgE (and pos FC in some patients)	85	5	56	21	80	92	10	0.22
	Dang # 2012	Australia	SPT ≥ 1 mm compared to neg control	81	7	51	19	81	88	6.70	0.22
	Keet 2013	US	Pos sensitization, regardless of history	23	10	25	3	89	71	3.09	0.16
	Bernard 2003	France	Pos history < 12 months	50	3	17	21	71	85	4.69	0.35
	Nicolaou 2011	UK	1) Pos SPT/sIgE regardless of ingestion 2) Pos history and (SPT ≥ 8 mm and/or sIgE ≥ 15 kU/l)	29	2	50	0	100	96	26.3	0
	Suratannon 2013	Thailand	Sensitization regardless of history/ingestion	13	1	20	6	68	95	14.3	0.33
sIgE to Ara h 2 multiplexed microarray
0.30 ISU/l	Keet 2013	US	Pos sensitization, regardless of history	21	8	27	5	81	77	3.53	0.25
0.30 ISU/l	Lopes de O. 2013	Germany	?	30	7	20	2	94	74	3.62	0.08
sIgE to Ara h 3 single-plexed assay
0.35 kU/l	Ebisawa 2012	Japan	Pos history or pos sensitization	11	6	25	15	42	81	2.18	0.72
	Glaumann 2012	Sweden	Pos history and pos SPT/sIgE	21	4	9	4	84	69	2.73	0.23
	Eller 2013	Denmark	Pos history	± 67	± 3	± 27	± 108	38	90	3.83	0.69
	Lieberman 2013	US	Pos history and pos SPT/sIgE (and pos FC in some patients)	51	6	55	55	48	90	4.80	0.58
	Suratannon 2013	Thailand	Sensitization regardless of history/ingestion	4	2	19	15	21	91	2.22	0.87
sIgE to Ara h 3 multiplexed microarray
0.30 ISU/l	Lopes de O. 2013	Germany	?	25	15	12	7	78	44	1.40	0.49
sIgE to Ara h 5 single-plexed assay
0.35 kU/l	Ebisawa 2012	Japan	Pos history or pos sensitization	9	7	24	17	35	77	1.53	0.84
0.35 kU/l	Suratannon 2013	Thailand	Sensitization regardless of history/ingestion	3	1	20	16	16	95	3.29	0.88
sIgE to Ara h 8 single-plexed assay
0.35 kU/l	Ebisawa 2012	Japan	Pos history or pos sensitization	11	6	25	15	42	81	2.18	0.72
	Glaumann 2012	Sweden	Pos history and pos SPT/sIgE	9	9	4	16	36	31	0.52	2.08
	Eller 2013	Denmark	Pos history	± 56	± 13	± 17	± 119	32	57	0.74	1.20
	Lieberman 2013	US	Pos history and pos SPT/sIgE (and pos FC in some patients)	37	35	26	69	35	43	0.61	1.51
	Suratannon 2013	Thailand	Sensitization regardless of history/ingestion	3	0	21	16	16	100	∞	0.84
sIgE to Ara h 9 single-plexed assay
0.35 kU/l	Ebisawa 2012	Japan	Pos history or pos sensitization	4	4	27	22	15	87	1.19	0.97
	Glaumann 2012	Sweden	Pos history and pos SPT/sIgE	3	2	11	22	12	85	0.78	1.04
	Eller 2013	Denmark	Pos history	± 15	± 5	± 25	±160	8.6	83	0.51	1.10
	Suratannon 2013	Thailand	Sensitization regardless of history/ingestion	5	1	20	14	26	95	5.48	0.77
PA, peanut allergy; TP, true positive; FP, false positive; TN, true negative; FN, false negative; Se, sensitivity; Sp, specificity; LR+, positive likelihood ratio; LR-, negative likelihood ratio; ∞, infinity; unk, unknown; FC, food challenge. ^Pos history, positive history of adverse reaction to peanut; pos SPT/sIgE, IgE to peanut extract ≥ ± 0.35 kU/l and/or SPT ≥ ± 3 mm; pos sensitization, not further specified in article * Study included 290 tolerant and 148 allergic patients. Exact values for TP, FP, TN, FP not known due to missing values for SPT and sIgE and use of logistic regression # Only peanut-sensitized subjects were used for tolerant group **Subselection of patients within study: 1) Pos history, 2) Pos SPT/sIgE or unclear history